Medtronic introduces breakthrough PulseSelect™ cardiac technology in India

Medtronic, a global leader in healthcare technology, has announced the launch of the PulseSelect™ system in India. The PulseSelect™ is a Pulsed Field Ablation (PFA) system designed to treat atrial fibrillation (AF), one of the most common heart rhythm disorders and a leading risk factor for stroke. Affecting over 7 million of the general population, its prevalence markedly increases with age.

While AF affects millions of people in India, awareness, diagnosis, and treatment rates remain relatively low. Many patients experience intermittent or mild symptoms that often go unrecognized, leading to delayed diagnosis and treatment.

Medtronic’s PulseSelect™ PFA system expands the company’s established atrial fibrillation portfolio, complementing its proven cryoablation technologies that are widely used around the world. Together, these therapies provide physicians with a comprehensive set of treatment options, enabling them to tailor care based on patient needs and procedural considerations while building on Medtronic’s long-standing clinical experience in AF management.

Unlike traditional treatments such as radiofrequency ablation (which uses heat) or cryoablation (which uses extreme cold), pulsed field ablation uses short electrical pulses instead of thermal energy. Because it does not rely on heat or freezing, it is designed to reduce the risk of damage to nearby tissues. The procedure can also be performed relatively quickly, which may help lower the risk of complications and support a smoother recovery after treatment . The safety and effectiveness of this technology have been demonstrated in Investigational Device Exemption (IDE) clinical trials.

Cryoablation remains a proven and effective therapy, while the introduction of the PulseSelect™ PFA system reflects Medtronic’s continued commitment to advancing innovative technologies that expand treatment options for physicians and the patients they serve.